Sunshine Biopharma Inc
Sunshine Biopharma Inc. is a pharmaceutical company engaged in offering and researching life-saving medicines in a variety of therapeutic areas, including oncology and antivirals. The Company has approximately 70 generic prescription drugs on the market in Canada. In addition, the Company is conducting a proprietary drug development program which is comprised of K1.1 mRNA, an mRNA-Lipid Nanoparticle targeted for liver cancer, and PLpro protease inhibitor, a small molecule for the treatment of SARS Coronavirus infections. The Company operates through two segments: Prescription Generic Pharmaceuticals (Generic Pharmaceuticals) and Nonprescription Over-The-Counter Products (OTC Products). The Company operates two wholly owned subsidiaries: Nora Pharma Inc., which has a portfolio of pharmaceutical products consisting of various prescription drugs on the market in Canada, and Sunshine Biopharma Canada Inc., which develops and sells nonprescription over-the-counter (OTC) products.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Sunshine Biopharma's stock with a target price of $300, indicating significant potential growth.
Financial Health
Sunshine Biopharma is showing solid revenue and cash flow, indicating a healthy business performance.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring SBFM
Analyst All-Stars
Take advantage of Wall Street's collective wisdom with this portfolio of top-rated stocks. These companies have earned strong 'Buy' ratings from respected financial analysts because of their solid fundamentals and potential for market outperformance.
Published: June 18, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Binary Clinical Catalysts
Trial readouts and regulatory milestones can drive large price moves; outcomes can be binary and uncertain, so performance may vary.
Financing & Dilution
Small biotechs often require additional capital. Monitor cash runway and fundraising terms, as new financing can dilute existing holders.
Partnership Potential
Collaborations or licensing deals with larger firms can materially change prospects, though they depend on positive data and successful negotiations.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
